Home
Chimerix

Chimerix Market Share Analysis for May 2026

About CMRX Chimerix, Inc. is . Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox.

Health > Biotechnology and Pharmaceuticals

Domainchimerix.com

Year Founded2000

Employees51 - 200

Annual Revenue$2M - $5M

Chimerix

Chimerix (including company regionals)

chimerix.com

See more website traffic and engagement information

Chimerix Revenue up to May 2026 is 2M - 5M

revenue generated by Chimerix top domains

Chimerix top domains revenue over 3 years

Revenue for Chimerix top domains

chimerix.com2M - 5M

See more with Sales Intelligence

Total visits to Chimerix's top domains

Understand Chimerix market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

chimerix.com108

See more with Sales Intelligence

Avg. visit duration in Chimerix's top domains

Analyze Chimerix engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Chimerix's top domains

See how Chimerix keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

chimerix.com1.00

See more with Sales Intelligence

Chimerix top competitors by domain

Top similar sites in May 2026, ranked by their affinity

emergentbiosolutions.comCompany NameEmergent BioSolutionsEmployees501 - 1000HQUnited States, Maryland, GaithersburgAnnual revenue> $1BTotal visits31.7KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Chimerix

These are the website technologies, by industry, used by Chimerix top domains

Payment & Currencies (8)

Cart Functionality

Advertising (3)

DoubleClick

Conversion & Analytics (3)

Google Analytics

Mobile (3)

Meta Viewport

More Technologies

9

See all

News & Signals from Chimerix

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsJazz Pharmaceuticals plc acquired Chimerix Inc. for $935M on Apr 21st '25.DUBLIN, April 21, 2025 /PRNewswire/ - Jazz Pharmaceuticals plc ("Jazz" or the "Company") today announced the successful completion of its acquisition of Chimerix, Inc. ("Chimerix") for approximately $935 million in cash.

NewsJazz Pharmaceuticals, Inc. acquires Chimerix Inc. for $935M.Jazz Pharmaceuticals has completed the acquisition of Chimerix, Inc. for $935 million, adding a potential therapy for H3 K27M-mutant diffuse glioma to its oncology portfolio.

NewsChimerix Inc. attended event JonesTrading Virtual Precision Medicine Symposium on Jan 29th '25.DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) - Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, and Tom Riga, Chief Operating and Commercial Officer, will participate in a fireside chat at the JonesTrading Virtual Precision Medicine Symposium on Monday, February 3, 2025 at 11:00 a.m. ET.